Abstract
ObjectiveFu's subcutaneous needling (FSN) has been shown potential positive effectiveness in clinical practice. However, its specific effects are still not clear. This study aims to evaluate the blinding effect of a non-penetrating sham FSN needle, developed for the first time by the authors' research team in healthy participants. Furthermore, to provide a reliable control tool to assess the specific effects of FSN. MethodsWe conducted a randomized, sham-controlled trial in 60 healthy participants divided into FSN group and sham FSN group in a 1:1 ratio. The participants were assessed according to blinding index (BI), pain intensity, sensation type and acceptability of needling. ResultsThe James' BI was (0.56, 95%CI [0.45, 0.67]) for two groups. The Bang's BI was (0.50, 95% CI [0.24, 0.76]) in the FSN group and (−0.36, 95% CI [−0.67, −0.07]) in the sham FSN group. There was no significant difference between needling pain intensity (P>0.05) and type of needling sensation. A total of 96.6% participants who received sham FSN and 86.6% participants who received FSN considered the needling acceptable or better. ConclusionThis study confirmed the effective blinding capability of the sham FSN needles in healthy participants, indicating that the novel non-penetrating sham FSN needle can be served as eligible control to evaluate the specific effects of FSN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
